EUVIMEDEUVIMED entdecken
Crossref

Harmonization of homologous recombination deficiency testing in ovarian cancer: Results from the MITO16A/MaNGO-OV2 trial

Cristin Roma, Riziero Esposito Abate, Alessandra Sacco, Daniela Califano, Laura Arenare, Francesca Bergantino, Carmela Pisano, Sabrina Chiara Cecere, Giovanni Scambia, Domenica Lorusso, Grazia Artioli, Giulia Tasca und 10 weitere

European Journal of Cancer · 2024-07 · 206 · 114127

DOI: 10.1016/j.ejca.2024.114127 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Cancer, 2024-07. Verfasst von Cristin Roma und 21 weiteren Autor:innen. Beteiligte Einrichtung: Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori - IRCCS - Fondazione G. Pascale, Naples, Italy. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Poly(ADP-ribose) Polymerase Inhibitors, Homologous Recombination. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Associazione Italiana per la Ricerca sul Cancro.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Homologous Recombination Deficiency (HRD) status predicts response to treatment with poly(ADP-ribose) polymerase inhibitors in Ovarian Cancer (OC) patients. The Myriad myChoiceCDx Assay is approved by Food and Drug Agency for the HRD assessment. Here we compared the HRD status obtained by three commercial panels with the results from Myriad reference test. METHODS: The HRD analysis was performed on DNA from formalin-fixed and paraffin-embedded tumor samples of 100 untreated OC patients for which Myriad assay results were available, using TruSight Oncology 500 HRD assay (Illumina), Oncomine Comprehensive Assay Plus (Thermo Fisher Scientific) and SOPHiA DDM HRD solution panel (SOPHiA Genetics). RESULTS: A good overall concordance with the reference method was demonstrated at three different levels: BRCA mutational status (from 94.4 % to 97.7 %), the genomic instability value (from 88.2 % to 95.3 %) and for the HRD status (from 90.4 % to 97.6 %). Moreover, a trend in favour of HRD positive patients for response rate, progression-free survival and overall survival similar to Myriad was observed for all three tests. DISCUSSION: Our data suggest the feasibility of commercial testing for assessing HRD status, with a good concordance with the reference method and association with clinical outcome.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsPoly(ADP-ribose) Polymerase InhibitorsHomologous RecombinationHumansFemaleMiddle AgedMutationAgedAdultGenetic TestingBRCA2 ProteinGenomic InstabilityBRCA1 ProteinBiomarkers, Tumor

Stichwörter der Autor:innen

Homologous Recombination DeficiencyOvarian CancerTargeted resequencing

Substanzen

Poly(ADP-ribose) Polymerase InhibitorsBRCA2 ProteinBRCA1 ProteinBiomarkers, Tumor

Autor:innen und Institutionen

  • Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori - IRCCS - Fondazione G. Pascale, Naples, Italy.
  • Microenvironment Molecular Targets Unit, Istituto Nazionale Tumori - IRCCS - Fondazione G. Pascale, Naples, Italy.
  • Clinical Trial Unit, Istituto Nazionale Tumori - IRCCS - Fondazione G. Pascale, Naples, Italy.
  • Uro-Gynecological Medical Oncology, Istituto Nazionale Tumori - IRCCS - Fondazione G. Pascale, Naples, Italy.
  • Department of Women and Child Health, Division of Gynecologic Oncology, Fondazione Policlinico Universitario A. Gemelli Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy; Department of Life Science and Pu…
  • Oncologia Medica, ULSS2 Marca Trevigiana, Treviso, Italy.

Förderung

  • Associazione Italiana per la Ricerca sul Cancro

Zitieren

APA

Roma, C., Esposito Abate, R., Sacco, A., Califano, D., Arenare, L., Bergantino, F., Pisano, C., Cecere, S. C., Scambia, G., Lorusso, D., Artioli, G., Tasca, G., Spina, A., Russo, D., Gadducci, A., De Angelis, C., Bologna, A., Marchini, S., Capoluongo, E. D., …, & Normanno, N. (2024). Harmonization of homologous recombination deficiency testing in ovarian cancer: Results from the MITO16A/MaNGO-OV2 trial. European Journal of Cancer, 206, 114127. https://doi.org/10.1016/j.ejca.2024.114127

Vancouver

Roma C, Esposito Abate R, Sacco A, Califano D, Arenare L, Bergantino F, et al. Harmonization of homologous recombination deficiency testing in ovarian cancer: Results from the MITO16A/MaNGO-OV2 trial. European Journal of Cancer. 2024;206:114127. doi:10.1016/j.ejca.2024.114127

BibTeX
@article{Roma2024,
  author = {Roma, Cristin and Esposito Abate, Riziero and Sacco, Alessandra and Califano, Daniela and Arenare, Laura and Bergantino, Francesca and Pisano, Carmela and Cecere, Sabrina Chiara and Scambia, Giovanni and Lorusso, Domenica and Artioli, Grazia and Tasca, Giulia and Spina, Anna and Russo, Daniela and Gadducci, Angiolo and De Angelis, Carmine and Bologna, Alessandra and Marchini, Sergio and Capoluongo, Ettore Domenico and Perrone, Francesco and Pignata, Sandro and Normanno, Nicola},
  title = {Harmonization of homologous recombination deficiency testing in ovarian cancer: Results from the MITO16A/MaNGO-OV2 trial},
  journal = {European Journal of Cancer},
  year = {2024},
  volume = {206},
  pages = {114127},
  doi = {10.1016/j.ejca.2024.114127}
}
Kostenlos starten →